^
Association details:
| Biomarker: | TP53 deletion |
|---|---|
| Cancer: | Marginal Zone Lymphoma |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
1680 Efficacy and Safety of Ibrutinib in Relapsed or Refractory Marginal Zone Lymphomas: The Real World Italian Experience
Published date:
11/02/2023
Excerpt:
At Cox regression multivariate analysis, pre-ibrutinib ECOG >1 (HR 2.09, 95% CI 1.19-3.67, p=0.01), elevated LDH (HR 2.56, 95% CI 1.13-5.79, p=0.024) and NMZL or dissMZL subtypes (HR 3.46, 95% CI 1.57-7.63, p=0.002) were associated to a worst PFS...TP53 mutation or deletion resulted significantly associated to inferior PFS in SMZL cases (p=0.015)... Not achieving ORR significantly predicted worst OS (HR 6.43, 95% CI 1.87-22.09, p=0.003).
